Εμφάνιση απλής εγγραφής

dc.creatorSkoufos, J.en
dc.creatorChristodoulopoulos, G.en
dc.creatorFragkou, I. A.en
dc.creatorTzora, A.en
dc.creatorGougoulis, D. A.en
dc.creatorOrfanou, D. C.en
dc.creatorTsiolaki, K.en
dc.creatorFthenakis, G. C.en
dc.date.accessioned2015-11-23T10:47:29Z
dc.date.available2015-11-23T10:47:29Z
dc.date.issued2007
dc.identifier10.1016/j.smallrumres.2006.07.012
dc.identifier.issn0921-4488
dc.identifier.urihttp://hdl.handle.net/11615/33086
dc.description.abstractThe trial was carried out in a sheep flock with mixed Mannheimia haemolytica/Mycoplasma spp. respiratory infection; 60 lambs were included therein and allocated as follows: lambs in group MH were subcutaneously injected with marbofloxacin (3.0 mg/kg bodyweight) on two occasions, once daily 2 days apart - lambs in group ML3 were given marbofloxacin (2.0 mg/kg) on three occasion, once daily for three consecutive days - lambs in group ML2 were given marbofloxacin (2.0 mg/kg) on two occasions, 2 days apart - lambs in group T were subcutaneously injected with tilmicosin (15 mg/kg) on two occasions, 4 days apart - lambs in group C were untreated controls. The lambs were monitored before and after treatment and the clinical findings were scored; they were euthanatised 42 days after treatment for pathological examination of the lungs. Groups were similar at the start of a field trial with respect to all parameters (general clinical condition, presence of nasal discharge, presence of ophthalmic discharge, results of lung auscultation) evaluated (P > 0.05). After treatment, no systemic or local adverse reactions were observed in any lamb. Forty-two days after treatment, the median general clinical assessment score of groups MH, ML3 and T was 0, that of group ML2 was I and that of group C lambs was 2 (P < 0.01). Treatment with marbofloxacin was associated with improved clinical scores; the results were similar for all evaluations 14 days after treatment and subsequently. Clinical cure rate 42 days after treatment was 100, 100, 42, 100 and 0% for group MH, ML3, ML2, T and C lambs, respectively (P < 0.01). After controlling for initial weight, treatment was found to have a significant effect on carcass weight (P < 0.01). Pairwise differences in lung lesion scores between any of the four treated groups and the untreated controls were significant (P < 0.02). It is concluded that marbofloxacin is effective against respiratory infections of lambs at a dose rate of 3.0 mg/kg bodyweight given on two occasions, once daily 2 days apart or at a dose rate of 2.0 mg/kg given on three occasions for three consecutive days. (C) 2006 Elsevier B.V. All rights reserved.en
dc.sourceSmall Ruminant Researchen
dc.source.uri<Go to ISI>://WOS:000247946900041
dc.subjectsheepen
dc.subjectpneumoniaen
dc.subjectfluoroquinolonesen
dc.subjectmarbofloxacinen
dc.subjectMannheimiaen
dc.subjecthaemolyticaen
dc.subjectMycoplasmaen
dc.subjectIN-VITRO ACTIVITYen
dc.subjectEXPERIMENTAL PASTEURELLOSISen
dc.subjectPHARMACOKINETICen
dc.subjectBEHAVIORen
dc.subjectTILMICOSINen
dc.subjectOXYTETRACYCLINEen
dc.subjectDANOFLOXACINen
dc.subjectDISEASEen
dc.subjectGOATSen
dc.subjectSHEEPen
dc.subjectSPECTINOMYCINen
dc.subjectAgriculture, Dairy & Animal Scienceen
dc.titleEfficacy of marbofloxacin against respiratory infections of lambsen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής